Advanced search    

Search: authors:"Neil R. Poulter"

6 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)

Aims/hypothesis The Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) was a double-blind, randomised, event-driven, treat-to-target prospective trial comparing the cardiovascular safety of insulin degludec with that of insulin glargine U100 (100 units/ml) in patients with ...

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality

Aims/hypothesis The double-blind Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) assessed the cardiovascular safety of insulin degludec. The incidence and rates of adjudicated severe hypoglycaemia, and all-cause mortality were also determined. This paper reports a secondary ...

Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients

Objective To estimate the absolute treatment effect of statin therapy on major adverse cardiovascular events (MACE; myocardial infarction, stroke and vascular death) for the individual patient aged ≥70 years. Methods Prediction models for MACE were derived in patients aged ≥70 years with (n = 2550) and without (n = 3253) vascular disease from the “PROspective Study of Pravastatin ...

Metabolic Syndrome, Independent of Its Components, Is a Risk Factor for Stroke and Death But Not for Coronary Heart Disease Among Hypertensive Patients in the ASCOT-BPLA

AJAY K. GUPTA BJORN DAHLOF PETER S. SEVER NEIL R. POULTER C a r d i o v a s c u l a r a n d OBJECTIVE - To evaluate whether in hypertensive patients the risk of cardiovascular disease is greater in

Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA)

recommended is 20% over 10 years (1,2); hence, we feel the final concluding statement of our article (5) is fully justified and commensurate with best evidence. NEIL R. POULTER, FRCP1 PETER S. SEVER, FRCP1

Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA)

PETER S. SEVER NEIL R. POULTER BJ ORN DAHL OF HANS WEDEL PHD RORY COLLINS GARETH BEEVERS MARK CAULFIELD SVERRE E. KJELDSEN ARNI KRISTINSSON GORDON T. MCINNES JESPER MEHLSEN MARKKU NIEMINEN FESC EOIN ... , Sweden. Address correspondence and reprint requests to Neil R. Poulter, International Centre for Circulatory Health, NHLI, Faculty of Medicine, Imperial College London, St. Marys Campus, 59 N. Wharf Rd